WuXi STA’s new drug product manufacturing facility passes first European MPA GMP Inspection

CDMO positioned to empower more customers to develop innovative drugs faster and more efficiently.

In 2017, WuXi STA merged with WuXi AppTec’s Pharmaceutical Development Services unit, realizing a seamless integration of chemistry, manufacturing and control (CMC) services. Two new commercial drug product facilities – in Shanghai and Wuxi City – have come into operation, enabling WuXi STA to support solid dosage drug development from preclinical to commercial, with several Phase III and commercial drug product projects underway.

WuXi STA has received FDA inspections at both its API and advanced intermediate manufacturing facility in Jinshan (Shanghai), and API R&D & manufacturing facility in Changzhou. As a leading global CDMO, WuXi STA has successfully passed inspections by regulatory bodies in the US, Canada, EU, Switzerland, China, Australia and New Zealand to supply APIs and GMP advanced intermediates for partners.

“We are very proud to have passed the European MPA GMP inspection,” commented Ms. Mei Hao, Vice President of Quality at WuXi STA. “We will continue to strengthen our global quality control system to meet the most stringent regulatory requirements and ensure the quality of services to our partners worldwide. It is a key milestone in our efforts to build geographically integrated capabilities for both drug product and substance development and manufacturing.”

“Quality is not just a core competency, it is ingrained throughout our culture at WuXi STA. The new facility passing the MPA’s GMP inspection is further proof of our commitment to the highest possible quality standards. We look forward to empowering more customers to develop innovative drugs faster and more efficiently for the benefit of patients around the world,” said Dr Minzhang Chen, CEO of WuXi STA.